Lipodystrophy, Metabolic Disorders, and Human Immunodeficiency Virus Infection: Aquitaine Cohort, France, 1999

Rodolphe Thiébaut, V. Daucourt, P. Mercié, Didier Koumavi Ekouévi, Denis Malvy, Philippe Morlat, M. Dupon, D. Neau, Sophie Farbos, Catherine Marimoutou, François Dabis, Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en AquitaineClinical 2000 · DOI

Abstract

The objective of this study was to estimate the prevalence of and risk factors for clinical lipodystrophy (LD) and metabolic disorders in human immunodeficiency virus (HIV) type 1-infected patients. A cross-sectional survey of the Aquitaine Cohort was performed in January 1999. The clinical diagnosis of LD was categorized as fat wasting (FW), peripheral fat accumulation (FA), and mixed syndromes (MS). Of the 581 patients studied, 61% were treated with protease inhibitors. The overall prevalence of LD was 38% (95% confidence interval [CI], 32-42): prevalence of FW was 16% (95% CI, 13-18); of FA, 12% (95% CI, 10-15); and of MS, 10% (95% CI, 8-13). The prevalences of metabolic abnormalities were 49% (95% CI, 44-53) for lipid disorders and 20% (95% CI, 17-23), for glucose disorders. Factors associated with LD were age (for FW and MS), male sex (for FW), AIDS stage (for MS), body mass index (for FW and FA), waist-to-hip ratio (for FA and MS), and duration of antiretroviral treatment (for FW).
BibTeX
@inproceedings{thiebaut2000lipodystrophy,
  author = {Rodolphe Thiébaut and V. Daucourt and P. Mercié and Didier Koumavi Ekouévi and Denis Malvy and Philippe Morlat and M. Dupon and D. Neau and Sophie Farbos and Catherine Marimoutou and François Dabis and Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine},
  title = {{Lipodystrophy, Metabolic Disorders, and Human Immunodeficiency Virus Infection: Aquitaine Cohort, France, 1999}},
  booktitle = {Clinical},
  year = {2000},
  doi = {10.1086/317477},
}

Loading related content...

Figure